Mammogen Appointed Robert S. Epstein to Board
The Newport Beach-based biotech company added the experienced industry leader to its Board of Directors.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust private diagnostics companies to prioritize patient health over their commercial expansion goals?
Mammogen has appointed Robert S. Epstein as an Independent Director to its Board of Directors. The Newport Beach-based company is currently developing genTRU-breast, a blood-based assay for breast cancer detection.
Why it matters
This appointment brings extensive corporate and diagnostic industry experience to Mammogen as it works toward clinical validation and commercialization. Epstein brings a track record of leadership in genomic and oncology-focused diagnostic firms to the company's growth phase.
Mammogen utilizes a platform based on RNA biomarker discovery and computational interpretation to develop diagnostic assays. The company is currently advancing its flagship genTRU-breast blood-based test through prospective clinical validation.
The players
Robert S. Epstein
He is an experienced director who serves as Chairman of Veracyte and previously spent 13 years on the board of Illumina.
Mammogen
This Newport Beach-based biotechnology company is developing a blood-based diagnostic assay for breast cancer known as genTRU-breast.
The details
Robert S. Epstein joins the board while concurrently serving as the Chairman of Veracyte and a board member at PinkDx. He previously held a chairmanship at Decipher Biosciences and spent over a decade guiding Illumina, providing Mammogen with deep expertise in scaling diagnostic technologies.
Timeline
Robert S. Epstein joined the Mammogen Board of Directors on October 13, 2026.
The Tech Race
The move aligns Mammogen with industry standards for scaling high-stakes diagnostic development where expert governance is critical for regulatory navigation. By securing leadership with deep experience in firms like Illumina, the company strengthens its position in the competitive liquid biopsy and early-detection market.
While this leadership change does not impact current consumer diagnostics, it marks a significant step toward the future availability of non-invasive breast cancer testing. Residents following local biotech advancements should monitor for upcoming clinical readout announcements from the firm.
The takeaway
Board appointments serve as a key indicator of a company's transition from research-heavy development to commercial preparation. Investors and stakeholders should observe how new leadership influences the velocity and focus of clinical trial benchmarks.
Further reading
Learn more about local sector developments in our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust private diagnostics companies to prioritize patient health over their commercial expansion goals?
